Allergan Restasis approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan's Restasis (cyclosporine ophthalmic emulsion 0.5%) clears FDA Dec. 23 for treatment of keratoconjunctivitis sicca (chronic dry eyes) after a protracted review. The original Feb. 24, 1999 NDA was granted priority status, but review was complicated by a unanimous advisory committee vote against approval in July 1999 and three "approvable" letters. In the NDA's four studies comparing Restasis to vehicle in 1,200 patients, a statistically significant increase in Schirmer wetting at six months was seen in 15% of Restasis patients. The agent will be available in early Apri
You may also be interested in...
What’s Next? Five Things To Look Out For In March
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval
Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.
Slovakia Becomes Second EU Country To OK Use Of Russian Vaccine
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: